Position in NVS
as of Jun 30, 2026
· filed Jul 9, 2026
Position Value
$709,941
+$17,984 QoQ
Shares Held
4,530
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.12%
of 13F equity value
Holder Rank
#744
of 1,603 holders
Holding Since
Dec 2023
11 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Stablepoint Partners, LLC holds $55,827,894 across 12 Drug Manufacturers - General names. NVS ranks #12 (1.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AMGN |
Amgen Inc
|
31,144 | $11,277,865 | |
| 2 | MRK |
Merck & Co., Inc.
|
67,206 | $8,635,971 | |
| 3 | JNJ |
Johnson & Johnson
|
29,950 | $7,606,401 | |
| 4 | GSK |
GSK plc
|
109,711 | $5,751,050 | |
| 5 | ABBV |
AbbVie Inc.
|
21,670 | $5,453,038 | |
| 6 | PFE |
Pfizer Inc
|
201,036 | $4,840,946 | |
| 7 | LLY |
ELI LILLY & Co
|
3,240 | $3,886,153 | |
| 8 | GILD |
Gilead Sciences, Inc.
|
23,047 | $2,911,757 |
All Filings in NVS
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $709,941 | 4,530 | Shares | Sole | 2026-07-09 | |
| 2026-03-31 | $691,957 | 4,530 | Shares | Sole | 2026-04-30 | |
| 2025-12-31 | $619,174 | 4,491 | Shares | Sole | 2026-01-13 | |
| 2025-09-30 | $586,313 | 4,572 | Shares | Sole | 2025-11-03 | |
| 2025-06-30 | $555,072 | 4,587 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $507,122 | 4,549 | Shares | Sole | 2025-04-11 | |
| 2024-12-31 | $442,663 | 4,549 | Shares | Sole | 2025-01-21 | |
| 2024-09-30 | $516,094 | 4,487 | Shares | Sole | 2024-10-11 | |
| 2024-06-30 | $477,686 | 4,487 | Shares | Sole | 2024-08-02 | |
| 2024-03-31 | $453,373 | 4,687 | Shares | Sole | 2024-04-23 | |
| 2023-12-31 | $433,060 | 4,289 | Shares | Sole | 2024-02-12 | |
| No filing history on record for this holder in this stock. | ||||||